State scope-of-practice laws impact the ability of nurse practitioners to prescribe medication-assisted treatment for patients with opioid use disorder.
The FDA stated that IV tramadol is not safe for the intended patient population.
IV acetaminophen is approved for the management of moderate to severe pain with adjunctive opioid analgesics, but limited data are available on the opioid-sparing effect of IV acetaminophen after surgical interventions.
Prescription pain medication abuse decreased significantly from 2007 to 2018.
From 2013 to 2018, the rate of drug overdose deaths involving cocaine increased nearly threefold.
Restrictions on intravenous opioid products at an academic medical institution during a critical drug shortage were not found to have significant impact on overall institutional opioid utilization.
Opioids prescribed by dentists may pose a threat for interactions with medications for depression or anxiety in older adults.
Opioid products approved by the FDA between 1997 and 2018 relied on short- or intermediate-term studies that did not adequately analyze safety outcomes.
Researchers developed a microsimulation model of the natural history of injection opioid use to assess long-term infective endocarditis mortality associated with injection opioid use in the United States.
Driving times to opioid treatment programs is longer than driving time to pharmacies, which may restrict access to methadone treatment.